Key Drivers
- Strong Free Cash Flow
- Rising Net Debt
- Weakening Liquidity
AIAI Summary
FMS is a recovery-and-execution trade—not a simple value buy—where strong free cash flow and potential gains from 5008X/value-based care must outweigh FDA remediation, reimbursement pressure, and worsening leverage; investors should wait for evidence of quality resolution and sustained margin improvement before treating its low valuation as compelling.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Free Cash Flow
- •Rising Net Debt
- •Weakening Liquidity
FMS offers reasonable valuation and strong cash flow, but rising leverage, weakening liquidity, and an unsustainably high quarterly payout warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Weak rebound
- •Support test
FMS remains in a short-term downtrend, with a modest bounce off $22.07 but reversal confirmation requiring a sustained move above $22.86–$22.97.
Small rebound from $22.07 to $22.20 suggests tentative stabilization
Sentiment & News
Key News Insights:
- •Institutional Accumulation
- •5008X Rollout
- •Reimbursement Risks
Fresenius Medical Care shows constructive momentum from institutional buying and 5008X-driven growth, but investors should monitor reimbursement, volume, and rollout-cost risks.
The news is moderately positive for FMS, though operational pressures may limit near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings